ABBV:NYE-AbbVie Inc (USD)

COMMON STOCK | Drug Manufacturers-General | NYE

Last Closing Price

USD 109.14

Change

0.00 (0.00)%

Market Cap

USD 192.87B

Volume

4.61M

Avg Analyst Target

USD 132.90 (+21.77%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois. Address: 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-24 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
JNJ Johnson & Johnson

N/A

USD430.99B 24.47 15.42
PFE Pfizer Inc

N/A

USD241.98B 18.43 12.25
LLY Eli Lilly and Company

N/A

USD233.17B 36.65 27.44
MRK Merck & Co. Inc

N/A

USD205.42B 36.95 17.69
NVS Novartis AG

N/A

USD189.94B 21.52 11.81
BMY Bristol-Myers Squibb Company

N/A

USD127.99B 194.50 19.86
GSK GlaxoSmithKline plc

N/A

USD100.06B 16.60 11.89
AGN Allergan plc

N/A

USD63.66B 22.00 28.44

ETFs Containing ABBV

Symbol Name Weight Mer Price(Change) Market Cap
AGGY WisdomTree Trust - Wisdom.. 0.00 % 0.12 %

N/A

USD1.07B
UEF0:F UBS ETF - Bloomberg Barcl.. 0.00 % 0.23 %

N/A

USD0.32B
SPYD:XETRA SSgA SPDR ETFs Europe I P.. 0.00 % 0.35 %

N/A

USD3.45B
QDVG:XETRA iShares V Public Limited .. 0.00 % 0.15 %

N/A

USD1.94B
QDVD:XETRA iShares II plc - iShares .. 0.00 % 0.35 %

N/A

USD0.37B
IS3S:XETRA iShares IV Public Limited.. 0.00 % 0.30 %

N/A

USD6.40B
ZPDH:F SSgA SPDR ETFs Europe II .. 0.00 % 0.15 %

N/A

USD0.27B
XDWH:F Xtrackers (IE) Public Lim.. 0.00 % 0.25 %

N/A

USD1.10B
WTEU:F WisdomTree US Equity Inco.. 0.00 % 0.29 %

N/A

USD0.01B
WTDY:F WisdomTree Issuer ICAV - .. 0.00 % 0.35 %

N/A

USD0.18M
WTD9:F WisdomTree US Equity Inco.. 0.00 % 0.29 %

N/A

USD0.05B
UEF9:F UBS ETF - Bloomberg Barcl.. 0.00 % 0.18 %

N/A

USD0.09B
UEF7:F UBS ETF - Bloomberg Barcl.. 0.00 % 0.18 %

N/A

USD0.33B
SYBR:F SSgA SPDR ETFs Europe I P.. 0.00 % 0.20 %

N/A

USD0.07B
SYBR:XETRA SSgA SPDR ETFs Europe I P.. 0.00 % 0.20 %

N/A

USD0.07B
SPYD:F SSgA SPDR ETFs Europe I P.. 0.00 % 0.35 %

N/A

USD3.45B
QDVG:F iShares V Public Limited .. 0.00 % 0.15 %

N/A

USD1.93B
QDVD:F iShares II plc - iShares .. 0.00 % 0.35 %

N/A

USD0.36B
IS3S:F iShares IV Public Limited.. 0.00 % 0.30 %

N/A

USD6.46B
SUSD:LSE SSgA SPDR ETFs Europe I p.. 0.00 % 0.20 %

N/A

USD0.14B
XUHC:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.12 %

N/A

USD0.62B
XSHC:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.12 %

N/A

USD0.62B
XDWH:LSE Xtrackers (IE) Public Lim.. 0.00 % 0.25 %

N/A

USD2.03B
WHEA:LSE SPDR MSCI World Health Ca.. 0.00 % 0.30 %

N/A

USD0.46B
USDV:LSE SSgA SPDR ETFs Europe I P.. 0.00 % 0.35 %

N/A

USD3.44B
UDVD:LSE SPDR® S&P US Dividend Ar.. 0.00 % 0.35 %

N/A

USD2.77B
SYBN:XETRA SSgA SPDR ETFs Europe I P.. 0.00 % 0.20 %

N/A

USD0.08B
UEF0:XETRA UBS ETF - Bloomberg Barcl.. 0.00 % 0.23 %

N/A

USD0.32B
UC86:LSE UBS ETF - Bloomberg Barcl.. 0.00 % 0.18 %

N/A

USD0.33B
HDLB ETRACS Monthly Pay 2xLeve.. 0.00 % 0.00 %

N/A

N/A
UDIV-B:CA Manulife Smart U.S. Divid.. 0.00 % 0.31 %

N/A

N/A
OUFH:XETRA Ossiam US ESG Low Carbon .. 0.00 % 0.00 %

N/A

N/A
UEF7:XETRA UBS ETF - Bloomberg Barcl.. 0.00 % 0.18 %

N/A

N/A
SPPD:XETRA SSGA SPDR ETFs Europe I p.. 0.00 % 0.40 %

N/A

USD0.02B
CBUF:XETRA iShares V Public Limited .. 0.00 % 0.25 %

N/A

USD0.39B
BLUM:XETRA Rize Ucits ICAV - Rize Me.. 0.00 % 0.65 %

N/A

USD0.04B
SDEI Tidal ETF Trust - Sound E.. 0.00 % 0.45 %

N/A

N/A
DIVZ Listed Funds Trust - True.. 0.00 % 0.65 %

N/A

N/A
HDIV Exchange Listed Funds Tru.. 0.00 % 0.75 %

N/A

N/A
MJO MicroSectors Cannabis 2X .. 0.00 % 0.95 %

N/A

N/A
MJJ MicroSectors Cannabis ETN.. 0.00 % 0.70 %

N/A

N/A
GBDV Global Beta ETF Trust - G.. 0.00 % 0.29 %

N/A

N/A
UEF8:XETRA UBS ETF - Bloomberg Barcl.. 0.00 % 0.23 %

N/A

USD0.46B
UDIV:CA Manulife Smart U.S. Divid.. 0.00 % 0.37 %

N/A

N/A
HIG-U:CA Brompton Global Healthcar.. 0.00 % 0.75 %

N/A

USD0.05B
ZPDH:XETRA SSgA SPDR ETFs Europe II .. 0.00 % 0.15 %

N/A

USD0.27B
XUHC:XETRA Xtrackers (IE) Public Lim.. 0.00 % 0.12 %

N/A

USD0.62B
XDWH:XETRA Xtrackers (IE) Public Lim.. 0.00 % 0.25 %

N/A

USD2.03B
XDEV:XETRA Xtrackers (IE) Public Lim.. 0.00 % 0.25 %

N/A

USD0.88B
WTEU:XETRA WisdomTree Issuer ICAV - .. 0.00 % 0.29 %

N/A

USD0.01B
WTDY:XETRA WisdomTree Issuer ICAV - .. 0.00 % 0.35 %

N/A

USD0.18M
WTD9:XETRA WisdomTree Issuer ICAV - .. 0.00 % 0.29 %

N/A

USD0.05B
VDIV:XETRA VanEck Vectors ETFs N.V... 0.00 % 0.00 %

N/A

USD0.05B
UEF9:XETRA UBS ETF - Bloomberg Barcl.. 0.00 % 0.18 %

N/A

USD0.09B
UC97:LSE UBS (Lux) Fund Solutions .. 0.00 % 0.20 %

N/A

USD0.27B
UC85:LSE UBS ETF - Bloomberg Barcl.. 0.00 % 0.23 %

N/A

USD0.08B
CUD:CA iShares US Dividend Growe.. 0.00 % 0.66 %

N/A

USD0.37B
LNGR Global X Aging Population.. 0.00 % 0.50 %

N/A

USD0.04B
XLV Health Care Select Sector.. 0.00 % 0.12 %

N/A

USD27.88B
XHC:CA iShares Global Healthcare.. 0.00 % 0.65 %

N/A

USD0.51B
VHT Vanguard Health Care Inde.. 0.00 % 0.10 %

N/A

USD17.94B
SDYL UBS ETRACS Monthly Pay 2x.. 0.00 % 0.30 %

N/A

USD9.68M
SDY SPDR S&P Dividend ETF 0.00 % 0.35 %

N/A

USD19.67B
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

N/A

USD0.22B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

USD1.19M
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

N/A

USD1.19M
PPH VanEck Vectors ETF Trust .. 0.00 % 0.35 %

N/A

USD0.23B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

N/A

USD0.37B
LQD iShares iBoxx $ Investmen.. 0.00 % 0.14 %

N/A

USD40.23B
JHMH John Hancock Multifactor .. 0.00 % 0.40 %

N/A

USD0.05B
HID:CA WisdomTree U.S. High Divi.. 0.00 % 0.40 %

N/A

USD4.31M
IYH iShares U.S. Healthcare E.. 0.00 % 0.43 %

N/A

USD2.66B
IBDQ iShares iBonds Dec 2025 T.. 0.00 % 0.10 %

N/A

USD1.16B
IBDN iShares Trust - iShares i.. 0.00 % 0.10 %

N/A

USD1.58B
IBDL iShares iBonds Dec 2020 T.. 0.00 % 0.10 %

N/A

USD0.95B
HDV iShares Core High Dividen.. 0.00 % 0.08 %

N/A

USD7.04B
FHLC Fidelity MSCI Health Care.. 0.00 % 0.08 %

N/A

USD2.70B
FDL First Trust Morningstar D.. 0.00 % 0.45 %

N/A

USD1.64B
ESGW Columbia Sustainable Glob.. 0.00 % 0.40 %

N/A

USD0.01B
DHS WisdomTree U.S. High Divi.. 0.00 % 0.38 %

N/A

USD0.81B
DEW WisdomTree Global High Di.. 0.00 % 0.58 %

N/A

USD0.08B
CURE Direxion Shares ETF Trust.. 0.00 % 1.01 %

N/A

USD0.17B
ZWH:CA BMO US High Dividend Cove.. 0.00 % 0.71 %

N/A

USD0.88B
CAPS:CA Evolve Active US Core Equ.. 0.00 % 0.70 %

N/A

USD3.62M
UC84:LSE UBS Barclays US Liquid Co.. 0.00 % 0.00 %

N/A

USD0.09B
BSUS:LSE UBS (Lux) Fund Solutions .. 0.00 % 0.25 %

N/A

USD0.11B
UC82:LSE UBS ETF - Bloomberg Barcl.. 0.00 % 0.23 %

N/A

USD0.04B
UC81:LSE UBS ETF - Bloomberg Barcl.. 0.00 % 0.18 %

N/A

USD0.33B
UC76:LSE UBS ETF - Bloomberg Barcl.. 0.00 % 0.18 %

N/A

USD0.09B
SXLV:LSE SSgA SPDR ETFs Europe II .. 0.00 % 0.15 %

N/A

USD0.26B
IUHC:LSE iShares S&P 500 Health Ca.. 0.00 % 0.15 %

N/A

USD1.94B
IHCU:LSE iShares S&P 500 Health Ca.. 0.00 % 0.15 %

N/A

USD1.69B
DHSP:LSE WisdomTree Issuer ICAV - .. 0.00 % 0.29 %

N/A

USD0.05B
DHSG:LSE WisdomTree Issuer ICAV - .. 0.00 % 0.35 %

N/A

USD5.58M
DHSD:LSE WisdomTree Issuer ICAV - .. 0.00 % 0.29 %

N/A

USD0.01B
DHSA:LSE WisdomTree Issuer ICAV - .. 0.00 % 0.29 %

N/A

USD0.05B
DHS:LSE WisdomTree Issuer ICAV - .. 0.00 % 0.29 %

N/A

USD0.01B
BIGT:LSE Legal & General UCITS ETF.. 0.00 % 0.49 %

N/A

USD0.04B
LIFE:CA Evolve Global Healthcare .. 0.00 % 0.45 %

N/A

USD0.01B
ZWH-U:CA BMO US High Dividend Cove.. 0.00 % 0.72 %

N/A

N/A
LS:CA Middlefield Healthcare & .. 0.00 % 1.31 %

N/A

USD0.09B
AWTM Tidal ETF Trust - Aware U.. 0.00 % 0.25 %

N/A

USD0.16B
DSTL Distillate U.S. Fundament.. 0.00 % 0.39 %

N/A

USD0.36B
IGIB iShares 5-10 Year Investm.. 0.00 % 0.06 %

N/A

USD11.87B
QUIG:CA Mackenzie US Investment G.. 0.00 % 0.17 %

N/A

USD0.39B
VSMV VictoryShares US Multi-Fa.. 0.00 % 0.35 %

N/A

USD0.16B
EVSTC Eaton Vance Stock NextSha.. 0.00 % 0.65 %

N/A

USD7.39M
FTXH First Trust Nasdaq Pharma.. 0.00 % 0.60 %

N/A

USD0.02B
NUBD Nuveen ESG U.S. Aggregate.. 0.00 % 0.20 %

N/A

USD0.26B
WBIY WBI Power Factor High Div.. 0.00 % 0.70 %

N/A

USD0.06B
AGNG Global X Aging Population.. 0.00 % 0.50 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.86% 50% F 35% F
Dividend Return 4.85% 100% A+ 80% B-
Total Return 6.71% 63% D 39% F
Trailing 12 Months  
Capital Gain 29.40% 88% B+ 56% F
Dividend Return 6.17% 88% B+ 77% C+
Total Return 35.57% 88% B+ 61% D-
Trailing 5 Years  
Capital Gain 77.32% 88% B+ 71% C-
Dividend Return 31.15% 100% A+ 85% B
Total Return 108.46% 88% B+ 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 16.09% 88% B+ 74% C
Dividend Return 4.50% 88% B+ 80% B-
Total Return 20.59% 88% B+ 79% C+
Risk Return Profile  
Volatility (Standard Deviation) 29.45% 13% F 38% F
Risk Adjusted Return 69.92% 75% C 75% C
Market Capitalization 192.87B 50% F 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 29.43 50% F 25% F
Price/Book Ratio 15.37 25% F 6% F
Price / Cash Flow Ratio 10.97 88% B+ 42% F
EV/EBITDA 15.42 63% D 40% F
Management Effectiveness  
Return on Equity 48.86% 88% B+ 93% A
Return on Invested Capital 17.48% 75% C 89% B+
Return on Assets 7.94% 63% D 88% B+
Debt to Equity Ratio 592.15% 13% F 5% F
Technical Ratios  
Short Ratio 1.43 100% A+ 63% D
Short Percent 0.77% 63% D 82% B-
Beta 0.83 13% F 68% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.